The addition of the first-in-class direct lytic agent exebacase (lysin CF-301) to standard-of-care (SOC) antibiotics demonstrated efficacy against Staphylococcus aureus bacteraemia (SAB), particularly difficult-to-treat methicillin-resistant SA (MRSA), compared with SOC antibiotics alone, according to the results of a phase II trial presented at ECCMID 2019.
The novel human monoclonal antibody suvratoxumab yielded a trend toward reducing the incidence of Staphylococcus aureus pneumonia (SAP) in high-risk, mechanically-ventilated intensive care unit (MV ICU) patients with an acceptable safety profile, according to data from the phase II SAATELLITE* trial presented at ECCMID 2019.
The selective cap-dependent endonuclease inhibitor baloxavir marboxil (hereafter baloxavir) effectively improves influenza symptoms in adolescent patients and those at high risk for influenza complications, according to two subanalyses of the CAPSTONE studies presented at ECCMID 2019.
The novel pleuromutilin antibiotic lefamulin - now in an oral therapy form - has demonstrated a favourable safety and tolerability profile for community-acquired bacterial pneumonia (CABP) in the LEAP* 2 study, the same result seen for intravenous (IV) lefemulin in the original LEAP 1 study.
Many patients prescribed antibiotics for suspected urinary tract infection (UTI) in the emergency department (ED) may not actually require them, according to a single-centre study from the UK presented at ECCMID 2019.
The combination of the antipseudomonal cephalosporin, ceftolozane, and an extended-spectrum β-lactamase inhibitor, tazobactam (ceftolozane/tazobactam), is noninferior to meropenem in the treatment of adults with ventilated nosocomial pneumonia (VNP), phase 3 data from the ASPECT-NP* trial have shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Infectious Diseases - Malaysia digital copy today!
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.